Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623424 · ClinicalTrials.gov registry record
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
A clinical trial of Stem Cell Transplant Complications, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- 255
- Enrollment target
- 1
- Study location
NCT04623424 is a study of Stem Cell Transplant Complications that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 255 participants, above the 169-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (51% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04623424, a study of Stem Cell Transplant Complications, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- 255 participants
- Enrollment target
- 1
- Study location
Study Summary
In this prospective study, the primary objective will be to investigate the association between the use of antibiotics administered during the admission period of Stem cell transplant (SCT) and the rate of overall change in microbiota composition across adjacent samples in time.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST intestinal microbiota
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2028-11-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623424
The ClinicalTrials.gov registry entry for NCT04623424 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 169-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (51% higher). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 1 intervention - of which intestinal microbiota is the first listed.
NCT04623424 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04623424 about?
NCT04623424 is a clinical study titled "Intestinal Microbiota in Stem Cell Transplant Transplant Admission". In this prospective study, the primary objective will be to investigate the association between the use of antibiotics administered during the admission period of Stem cell transplant (SCT) and the rate of overall change in microbiota composition across adjacent samples in time.
What is the current status of trial NCT04623424?
This trial is currently recruiting. The enrollment target is 255 participants. The study started on 2020-11-03. Estimated completion is 2028-11-03.
What conditions does trial NCT04623424 study?
This clinical trial studies the following conditions: Stem Cell Transplant Complications.
What interventions are being tested in trial NCT04623424?
The interventions under investigation include: intestinal microbiota (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04623424?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623424 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
RECRUITING · Phase 2
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RECRUITING · Phase 3
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.